SCHEMBL23925547

SCHEMBL23925547

Cc1ccc2[nH]cc(CCNC(=O)Nc3cccc(F)c3)c2c1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.78
SMN1; SMN2 Q16637 4/20 0.78
POLB P06746 1/20 0.78
MEN1 O00255 4/20 0.74
KMT2A Q03164 4/20 0.74
MTNR1A P48039 2/20 0.61
MTNR1B P49286 2/20 0.61
TRPV1 Q8NER1 4/20 0.60
TP53 P04637 1/20 0.59
GOT1 P17174 2/20 0.59
FAAH O00519 1/20 0.58
NOTUM Q6P988 1/20 0.57
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
SNCA P37840 1/20 0.56
ALOX12 P18054 1/20 0.56
HTT P42858 1/20 0.56
LMNA P02545 1/20 0.56
ALOX15 P16050 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23925614 0.88 MAPT (0.80) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925617 0.86 MAPT (0.87) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL26430695 0.86 MAPT (0.83) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925476 0.84 MAPT (0.76) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925499 0.83 MAPT (0.68) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925546 0.82 GOT1 (0.75) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925548 0.81 TSHR (0.68) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925487 0.78 MAPT (0.79) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL26430691 0.78 MAPT (0.72) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL9938370 0.77 SNCA (0.81) SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC 2023-04-27 US claimed
WO-2021211123-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-10-21 WO claimed
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC 2023-04-27 US disclosed
WO-2021211123-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA TLR4, TLR5, TLR1 MAPT 1718/4885SMN1; SMN2 4580/4885POLB 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.